dexing polymorphisms in coding or noncoding regions will provide largely congruent classifications of isolates into clonal lineages. PFGE is considered the gold standard in typing for a variety of bacteria, including S. aureus (4 -7 ) . This method is technically demanding, however, with a low throughput and difficulties in achieving interlaboratory comparability and standardization. PFGE may be too discriminatory for long-term epidemiologic investigations, and it fails to account for genetic changes within a single, globally distributed clonal lineage of MRSA (6, 9 ) . With the indexing of allelic polymorphisms in 7 neutral housekeeping genes (9 ), MLST has been considered the reference method for defining the core genetic population structure of S. aureus (8 ) . As a DNA sequencing-based method, MLST allows full reproducibility of results between laboratories, but it has lower resolution and remains too labor-intensive and costly for use as a primary typing tool. spa typing, which evaluates sequence polymorphism in the variable X region of the spa gene, which encodes staphylococcal surface protein A, has become popular for MRSA typing (6, 10, 11 ) . As a sequencing-based method for a single locus, spa typing possesses moderate discriminatory power, between PFGE and MLST; however, repeat-based spa typing is subject to misclassification bias due both to horizontal DNA transfer and to recombination and homoplasy (16 ) .
Typing techniques that are rapid, easy, and relatively inexpensive are based on PCR amplification methods, which include rep-PCR typing and MLVA. rep-PCR typing, which is based on multicopy elements in the staphylococcal genome, has been shown to be variably discriminatory but poorly reproducible among laboratories when in-house protocols are used (14 ) . A kit-based rep-PCR assay combined with a commercial fingerprint-analysis platform (DiversiLab typing system; bioMérieux) showed excellent reproducibility and moderate discriminatory power as a screening tool to rule out potential MRSA outbreaks in hospitals (7, 15 ) . MLVA schemes share the rep-PCR advantages of rapid turnaround times and high throughput, but their discriminatory power depends on the number and types of loci for variable number of tandem DNA repeats/staphylococcal interspersed repeat units that are analyzed. As with rep-PCR, no stan-dard MLVA protocol or standardized nomenclature is yet available for type/subtype assignment.
Thus, there is an ongoing need for rapid and definitive genotyping systems, especially ones that can be applied in clinical laboratories. In this issue of Clinical Chemistry, a group of scientists from U.S. Genomics and Mount Auburn Hospital describe a new genomic mapping/typing technology, direct linear analysis (DLA), which enables rapid, large-scale mapping of whole genomes by directly analyzing single linearized fragments of genomic DNA molecules of up to 250 kb in length from a simple restriction enzyme digest (17 ) . As shown in Fig. 1 , short universal probes are designed to hybridize to these fragments. Proprietary microfluidics methods are then used to stretch the DNA to full contour length and carry the individual molecules through a focused spot of laser light. The excited probe's fluorescence is detected in a linear fashion. The specific locations of the probes generate a spatially resolved map unique to each organism. By leveraging these unique characteristics of individual DNA molecules, one can compare DNA maps against a database of known reference maps associated with human and microbial species to search for a match. This approach provides a method with the potential to rapidly and accurately characterize a given DNA species in a complex sample for diverse applications. In this study, the authors have successfully applied this technique for molecular typing of S. aureus. The process can be completed within 8 h with a discriminatory power comparable to that of PFGE (17 ) .
Performed in a microfluidics chip, the DLA technology has the following unique characteristics: (a) Typing patterns are generated directly from genomic DNA, without the need for an amplification step. This feature avoids any amplification-based bias and decreases costs and test turnaround times. (b) Typing patterns can be generated from complex samples and may be used to simultaneously determine multiple species in a single sample with a single test. (c) Because very few molecules are required, typing patterns can be created directly from a clinical sample without the need for prior culturing. (d) Typing patterns can be generated for any known or unknown species, whether or not complete primary sequence information is available. (e) Typing patterns can be generated from a universal reagent set without the need for organismspecific reagents.
This novel technique has 2 promising advantages. First, it possesses the unique ability to distinguish microbial organisms at both the "macro" and "micro" levels. Like PFGE, it distinguishes macrogenomic fragments by length. In addition, it provides microsequence-dependent information within each fragment, like MLST. Although the DLA assay analyzes a smaller proportion of the genome and a narrower size range than PFGE and although the sequence-based mapping information is not as discriminatory as the nucleic acid sequences given by MLST, the combination of both features allows the DLA technology to possess a discriminatory power equivalent to that of PFGE and MLST. Second, the entire test procedure has a turnaround time of Ͻ8 h, with typing results reported on the same day. DLA is thus superior in this respect to both PFGE and MLST, which require several days to complete the time-consuming procedures.
Although promising, the DLA assay is still in its infancy. The clinical relevance of the DLA-typing data has not been investigated. Although few methods provide a true measure of genetic relatedness, criteria for defining different categories of relatedness (e.g., "identical/indistinguishable," "highly related but distinguishable," "moderately related," and "unrelated") should be established (18 ) . The database should be extended to cover DLA types from all S. aureus prototypes and clones and to create nomenclature for DLA type assignment. I look forward to a well-designed, multicenter trial for full validation of the DLA assay for S. aureus typing in which a reference standard based on laboratory, clinical, and epidemiology information is incorporated. 
